Related Experiment Video

Updated: Aug 14, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K

Discovery of Coumarin-Based MEK1/2 PROTAC Effective in Human Cancer Cells

Chao Wang1, Han Wang2, Cangxin Zheng2

  • 1National Pharmaceutical Teaching Laboratory Center, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.

ACS Medicinal Chemistry Letters
|January 19, 2023
PubMed

Insights

Researchers developed P6b, a novel MEK PROTAC, to overcome resistance to MEK1/2 inhibitors. This non-diarylamine compound effectively degrades MEK1/2 and inhibits cancer cell growth, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • The RAF/MEK/ERK pathway regulates tumor cell proliferation, differentiation, and apoptosis.
  • MEK1/2 is a critical kinase target within this pathway, with ERK1/2 as its primary substrate.
  • Acquired resistance to existing MEK1/2 inhibitors, often featuring a diarylamine scaffold, remains a significant clinical challenge.

Purpose of the Study:

  • To design and synthesize novel MEK1/2 degraders with a non-diarylamine scaffold.
  • To identify potent MEK PROTACs effective against cancer cells.
  • To overcome acquired resistance associated with traditional MEK inhibitors.

Main Methods:

  • Design and synthesis of a series of MEK1/2 degraders based on a coumarin derivative.
  • Evaluation of degradation potency using DC50 values for MEK1 and MEK2.
  • Antiproliferation assays to assess efficacy in human cancer cell lines (A375 and A549).

Main Results:

  • Compound P6b demonstrated potent degradation of MEK1 (DC50=0.3 μM) and MEK2 (DC50=0.2 μM).
  • P6b significantly inhibited the growth of A375 cells (IC50=2.8 μM) compared to A549 cells (IC50=27.3 μM).
  • P6b represents a novel non-diarylamine scaffold for MEK PROTAC development.

Conclusions:

  • P6b is identified as a potent MEK PROTAC with a unique non-diarylamine structure.
  • This compound effectively degrades MEK1/2 and exhibits significant antiproliferative activity in human cancer cells.
  • P6b offers a promising new therapeutic avenue for overcoming resistance in MEK-driven cancers.

More Related Videos

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.5K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K